Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration [PDF]
Background/Objectives: Carvedilol is an adrenergic blocker FDA-approved to improve outcomes in heart failure with reduced ejection fraction. Clinical trials examining whether carvedilol may be cardioprotective in the setting of cancer therapy-induced ...
Asma Boukhalfa +14 more
doaj +2 more sources
Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers [PDF]
A Carvedilol is a member of BCS class II, it has a low solubility and bioavailability. This work intends to increase the solubility of carvedilol using a multicomponent crystal method.
Iyan Sopyan +3 more
doaj +5 more sources
Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial [PDF]
Background Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (
Dong-Ju Choi +14 more
doaj +2 more sources
Therapeutic Effects of Carvedilol on Intestinal Mucosa in Intestinal Ischemia Reperfusion Injury Model; An Experimental Study [PDF]
Background: Intestinal ischemia–reperfusion (I/R) injury is a critical clinical condition associated with high morbidity and mortality, with acute mesenteric ischemia carrying mortality rates of 60%–80%.
Fatma Tugba Güçlü Güvenç +4 more
doaj +2 more sources
Exposure to UVR suppresses the immune system, which plays a primary role in skin cancer etiology. The β-blocker carvedilol prevents UV-induced skin cancer, but the mechanism is unknown. This study examined the effects of carvedilol and its enantiomers on
Ayaz Shahid +3 more
doaj +2 more sources
Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta‐blockers. Degenerative
Wei‐Chieh Lee +5 more
doaj +2 more sources
Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-PedersenDepartment of Cardiology, Bispebjerg University Hospital, Copenhagen, DenmarkAbstract: Beta-blockers have been shown to improve survival in patients with chronic heart ...
Britt Kveiborg +3 more
doaj +1 more source
Metabolomic profiling of cellular responses to carvedilol enantiomers in vascular smooth muscle cells. [PDF]
Carvedilol is a non-selective β-blocker indicated in the treatment of hypertension and heart failure. Although the differential pharmacological effects of individual Carvedilol enantiomer is supported by preceding studies, the cellular response to each ...
Mingxuan Wang +3 more
doaj +2 more sources
Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension [PDF]
Background: The therapeutic benefits of β-blockers are well established in left heart failure. The Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure [PAHTCH] study showed safety and possible benefit of carvedilol in pulmonary ...
Hoi I Cheong +12 more
doaj +2 more sources
Dandan Liu,1 Hao Pan,2 Fengwei He,1 Xiaoyu Wang,3 Jinyu Li,3 Xinggang Yang,3 Weisan Pan31Department of Pharmaceutical Engineering, School of Biomedical and Chemical Engineering, Liaoning Institute of Science and Technology, Benxi, People’s Republic
Liu DD +6 more
doaj +1 more source

